Table 1

Case overview

CaseAgeSexIMDCSubtypeNGSarcomatoid featuresICIPrior
Tx
Time to irAIN
(months)*
Biopsy proven AIN?Cr [mg/dL] (eGFR [mL/min/1.73 m2])irAIN TxirAIN Tx duration
(months)
BRDOR
(months)
BaselinePeakRecovery
171MInt.ccRCC410%NPazo12.8Yes1.3 (55)2.25 (35)1.48 (50)NoneN/ACR52§
270MPoorccRCC2**AbsentNPazo
PT2385
Axi
10.8Yes1.5 (42)10 (5)1.85 (36)Mpred 500 mg3PR‡14
348MInt.ccRCC3**AbsentN+INone1.4No1.2 (>60)2.45 (28)1.28 (60)Pred 1 mg/kg daily††
Myco 1.5 g BID
4CR29
458MPoorpRCC3AbsentN+INone2.1Yes0.8 (>60)2.65 (37)1.74 (49)Pred 1 mg/kg daily3PR8
  • *From start of ICI therapy.

  • †Maximal immunosuppressive therapy, tapered over treatment duration.

  • ‡Following pseudoprogression.

  • §At 36 months post-ICI initiation, patient developed an asymptomatic brain lesion which was irradiated.

  • ¶Ongoing.

  • **Diagnosis via biopsy of primary tumor.

  • ††Tapered over 7 weeks

  • Axi, axitinib; BID, twice daily; BR, best response; ccRCC, clear cell RCC; CR, complete response; DOR, duration of response; I, Ipilimumab; IMDC, international metastatic RCC database risk group score at the time of starting ICI; Int, intermediate risk; Mpred, methylprednisolone; Myco, mycophenolate; N, Nivolumab; NG, nuclear grade; Pazo, Pazopanib; PR, partial response; pRCC, papillary RCC; Pred, Prednisone; PT2385, experimental HIF-2α inhibitor; Tx, treatment.